ETR:MRKMerck KGaA Stock Price, Forecast & News

€105.80

+4.60 (+4.55 %)

(As of 05/28/2020 04:00 PM ET)

Add

Compare

Today's Range

€101.35

Now: €105.80▼

€106.10

50-Day Range

€93.26

MA: €102.81▼

€107.95

52-Week Range

€76.22

Now: €105.80▼

€125.95

Volume681,033 shs

Average VolumeN/A

Market Capitalization$13.67 billion

P/E Ratio28.91

Dividend Yield2.50%

BetaN/A

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments. The company also provides life science products and services for use in the discovery, development, and manufacture of drug therapies, as well as in laboratories; and specialty chemicals for use in displays, computer chips, surfaces, Integrated circuits, microelectronic systems, anti-reflection coatings, and cosmetics. It has alliances with Pfizer Inc., Bristol-Myers Squibb Company, Intrexon Corporation, Avillion LLP., F-star Delta Ltd, SFJ Pharmaceuticals Group, Alibaba Health, Checkmate Pharmaceuticals, Solvias, and Leap Therapeutics, Inc., as well as a collaboration with Daiichi Sankyo Company, Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Merck KGaA.

2.9 Community Rank

Outperform Votes
Merck KGaA has received 36 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Merck KGaA has received 27 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Merck KGaA has received 57.14% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Merck KGaA and other stocks. Vote “Outperform” if you believe MRK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.

2.5 Dividend Strength

Dividend Leadership
Merck KGaA is a leading dividend payer. It pays a dividend yield of 2.50%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Merck KGaA does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Merck KGaA is 71.04 %. This payout ratio is at a healthy, sustainable level, below 75%.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Merck KGaA insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Merck KGaA is 28.91, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.95.
Price to Earnings Ratio vs. Sector
The P/E ratio of Merck KGaA is 28.91, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.23.
Price to Book Value per Share Ratio
Merck KGaA has a P/B Ratio of 2.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.08 out of 5 stars

Industry, Sector and Symbol

Stock Exchange ETR

Industry Drug Manufacturers - Specialty & Generic

Sub-IndustryN/A

SectorMedical

Current SymbolETR:MRK

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.merckgroup.com

Phone49 6151 72 0

Debt

Debt-to-Equity Ratio74.48

Current Ratio0.93

Quick Ratio0.56

Price-To-Earnings

Trailing P/E Ratio28.91

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$16.78 billion

Price / Sales0.82

Cash Flow€3.69 per share

Price / Cash Flow28.64

Book Value€42.73 per share

Price / Book2.48

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees51,039

Outstanding Shares129,242,000

Market Cap$13.67 billion

Next Earnings Date8/6/2020 (Estimated)

OptionableOptionable

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

Merck KGaA (ETR:MRK) Frequently Asked Questions

How has Merck KGaA's stock been impacted by COVID-19 (Coronavirus)?

Merck KGaA's stock was trading at €98.68 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MRK shares have increased by 7.2% and is now trading at €105.80. View which stocks have been most impacted by Coronavirus.

When is Merck KGaA's next earnings date?

Merck KGaA is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Merck KGaA.

Has Merck KGaA been receiving favorable news coverage?

News articles about MRK stock have trended extremely positive recently, InfoTrie reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Merck KGaA earned a coverage optimism score of 4.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term. View the latest news aboutMerck KGaA.

Who are some of Merck KGaA's key competitors?

Some companies that are related to Merck KGaA include Canopy Growth (WEED), Bausch Health Companies (BHC), Hikma Pharmaceuticals (HIK), Evotec (EVT), Aurora Cannabis (ACB), Aphria (APHA), Knight Therapeutics (GUD), Ecofibre (EOF), HLS Therapeutics (HLS), OrganiGram (OGI), Hexo (HEXO), Next Science (NXS), ICC Labs (ICC), HEXO (HEXO) and Benchmark (BMK). View all competitors.

What other stocks do shareholders of Merck KGaA own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck KGaA investors own include Berkshire Hathaway (BRK.B), Walt Disney (DIS), Eli Lilly And Co (LLY), Medtronic (MDT), AbbVie (ABBV), Abbott Laboratories (ABT), Adobe (ADBE), Aldeyra Therapeutics (ALDX), Ares Capital (ARCC) and Boeing (BA).

Who are Merck KGaA's key executives?

Merck KGaA's management team includes the following people:

Dr. Stefan Oschmann, Chairman of Exec. Board & CEO (Age 62)
Dr. Marcus Kuhnert, CFO & Member of Exec. Board (Age 51)
Dr. Kai Beckmann, CEO of Performance Materials & Member of the Exec. Board (Age 54)
Dr. Udit Batra, CEO of Life Science & Member of Exec. Board (Age 48)
Ms. Belén Garijo López M.D., CEO of Healthcare & Member of the Exec. Board (Age 59)

What is Merck KGaA's stock symbol?

Merck KGaA trades on the ETR under the ticker symbol "MRK."

What is Merck KGaA's stock price today?

One share of MRK stock can currently be purchased for approximately €105.80.

How big of a company is Merck KGaA?

Merck KGaA has a market capitalization of $13.67 billion and generates $16.78 billion in revenue each year. Merck KGaA employs 51,039 workers across the globe.

What is Merck KGaA's official website?

The official website for Merck KGaA is www.merckgroup.com.

How can I contact Merck KGaA?

The company can be reached via phone at 49 6151 72 0.

This page was last updated on 5/28/2020 by MarketBeat.com Staff